Menopause hormone therapy relieves hot flashes and night sweats better than any other treatment, and it protects bone. It also has real risks, and those risks depend heavily on your age, how long it has been since menopause, your health history and the type of hormones you take. For many healthy women under 60, the leading guideline finds the benefits outweigh the risks.
Here is what the research actually shows, and why the answer changed after 2002.
Why so many women were told to stop
In 2002, one arm of the Women's Health Initiative (WHI), a large set of randomized trials in postmenopausal women, was stopped early after combined estrogen and progestin was linked to more breast cancer. Prescriptions fell sharply, and many women were left with the impression that hormone therapy was dangerous for everyone.
The WHI enrolled women with an average age in their 60s, many of them years past menopause. Later analyses and decades of follow-up gave a more detailed picture: the balance of benefit and risk looks quite different for women who start near menopause than for women who start much later.
What hormone therapy does well
Hot flashes and night sweats
A Cochrane review of 24 randomized trials with 3,329 women found oral hormone therapy reduced weekly hot flush frequency by 75% compared with placebo [1]. Placebo helped too (hot flashes fell 57.7% from baseline on placebo), which is common in symptom trials, but hormone therapy worked far better.
Bone
In the WHI trial of estrogen plus progestin, 8.6% of women on hormone therapy had a fracture, compared with 11.1% on placebo (hazard ratio 0.76) [2].
The risks
Breast cancer
The type of therapy matters. In long-term follow-up of the WHI trials [3]:
- In women with a uterus, estrogen plus progestin raised breast cancer cases: 584 compared with 447 on placebo (hazard ratio 1.28).
- In women without a uterus, estrogen alone lowered them: 238 compared with 296 on placebo.
Women with a uterus need a progestogen with estrogen, because estrogen alone raises the risk of cancer of the uterine lining.
Heart disease, stroke, blood clots and dementia
Age and timing matter most here. The North American Menopause Society's 2022 position statement says that for women who start hormone therapy more than 10 years after menopause, or after age 60, the benefit-risk ratio is less favorable, because of greater absolute risks of coronary heart disease, stroke, venous thromboembolism (blood clots) and dementia [4]. The same statement notes that lower doses and estrogen applied to the skin may lower some of these risks.
Who is it right for?
The guideline's central conclusion: "For women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome VMS and prevention of bone loss" [4]. VMS means vasomotor symptoms: hot flashes and night sweats.
Hormone therapy is usually not appropriate for women who have had breast cancer, a blood clot, a stroke or heart attack, or unexplained vaginal bleeding. For women who can't or prefer not to take hormones, non-hormonal prescription options can reduce hot flashes.
Questions to ask your doctor
- How old was I at menopause, and how long ago was it?
- Do I need a progestogen (do I still have a uterus)?
- Would a patch or gel suit me better than a tablet?
- How will we check whether it's working, and when will we review it?
- What are my non-hormonal options?
The bottom line
Menopause hormone therapy is not right or wrong for everyone. It is a medical decision that depends on your age, your timing, your history and your symptoms, and it deserves an unhurried conversation with a doctor who knows your case.
At Ora, Dr. Chaniotakis reviews your symptoms, history and labs, explains the benefits and risks that apply to you, and adjusts your plan over time. Learn more about our menopause care, or read Perimenopause: the signs, how long it lasts and what helps.
Sources
- MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004;(4):CD002978. doi.org/10.1002/14651858.CD002978.pub2
- Cauley JA, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA. 2003;290(13):1729–1738. doi.org/10.1001/jama.290.13.1729
- Chlebowski RT, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials. JAMA. 2020;324(4):369–380. doi.org/10.1001/jama.2020.9482
- The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–794. doi.org/10.1097/GME.0000000000002028